Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.
about
The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis BIdentification of anti-HBV activities in Paeonia suffruticosa Andr. using GRP78 as a drug target on Herbochip®.Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks.Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection.Entecavir for the treatment of chronic hepatitis B.Hepatocyte turnover during resolution of a transient hepadnaviral infection.Avian hepatitis B viruses: molecular and cellular biology, phylogenesis, and host tropism.Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.Mouse models for therapeutic vaccination against hepatitis B virus.DNA vaccine: a promising new approach for chronic hepatitis B therapy.Present and future DNA vaccines for chronic hepatitis B treatment.Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo.Investigational drugs in development for Hepatitis D.The Pekin duck programmed death-ligand 1: cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis.Establishment and assessment of two methods for quantitative detection of serum duck hepatitis B virus DNACombination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model.Antiviral effects of PNA in duck hepatitis B virus infection model.Activity of nucleic acid polymers in rodent models of HBV infection.In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes.
P2860
Q27007019-CB4BAADF-51E6-45D5-AD68-DA5FE5F04F53Q33595736-F1DBF3AD-DD4F-4DC9-9A85-0F4AABC50788Q33755065-04FA1668-244C-40D2-8326-9C195FB5C70BQ33984190-18BD04D8-BB3D-413E-A96B-E08AC230DCDCQ34975067-556A20BA-7141-40C4-97C4-9377719CC616Q35735964-AB01E90A-C2C3-4E9B-8CA0-578006DE6DF7Q35839139-63E956AA-953D-4082-A1AD-A3EDE1CA6D1CQ35964745-E0CAE533-D099-44EC-B0EA-01CB0DE159E1Q36161444-5CED4421-9570-487E-B213-63B61ABBD41FQ36700708-74A792F4-F793-4CA0-A2C7-019BEB73CC7CQ37291331-F9A64417-F2CD-40A8-83A9-4865C0258768Q38293590-98092BAC-6543-4ABA-95C8-23A672C1C7AAQ38604885-5344DF14-2259-4AD3-A2F5-65A9B86ACB7CQ38790065-9FE82495-A520-4BC4-890A-1A13FEC7CEADQ39368000-1948B349-D247-493D-A173-089D42FCC5F0Q40113645-2FB19F17-E832-4FD4-9276-6C8E5B0B1C06Q41628406-03FB65A9-322F-45AB-8B9B-BA9A3A9B5331Q41983135-72F01878-ED03-4BF8-BDFD-14FC1F926B2FQ43064406-7A7A63ED-B9E2-4323-8C22-9B07C9508FE3Q45399993-7C99441F-0C7A-4E66-9F05-37C9B67DD29BQ46263692-10E5B31B-6304-4D13-BEE5-E43C460165DFQ46773926-3246466F-2F77-4A30-AA6E-FC84D303E57C
P2860
Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Entecavir therapy combined wit ...... k hepatitis B virus infection.
@ast
Entecavir therapy combined wit ...... k hepatitis B virus infection.
@en
type
label
Entecavir therapy combined wit ...... k hepatitis B virus infection.
@ast
Entecavir therapy combined wit ...... k hepatitis B virus infection.
@en
prefLabel
Entecavir therapy combined wit ...... k hepatitis B virus infection.
@ast
Entecavir therapy combined wit ...... k hepatitis B virus infection.
@en
P2093
P2860
P1476
Entecavir therapy combined wit ...... k hepatitis B virus infection.
@en
P2093
Allison R Jilbert
Darren S Miller
Ieva Kotlarski
Patricia L Marion
Richard J Colonno
Wendy K Foster
P2860
P304
P356
10.1128/AAC.47.8.2624-2635.2003
P407
P577
2003-08-01T00:00:00Z